Table 1 Features of incretin-related therapy
| Â | Administration | Clearance | Side effects | |
|---|---|---|---|---|
GLP-1R agonist | Subctaneous | Â | Weight loss | Gastrointestinal tract (GIT) |
Exenatide | Twice a day, once a week | Renal | + | ++/±* |
Liraglutide | Once a day | Extrarenal | + | + |
DPP-4 inhibitor | Oral |  | → | → |
Sitagliptin | Once a day | Renal | → | → |
Vildagliptin | Twice a day | Renal | → | → |
Saxagliptin | Once a day | Renal | → | → |
Linagliptin | Once a day | Extrarenal | → | → |
Anagliptin | Twice a day | Renal | → | → |
Teneligliptin | Once a day | Extrarenal > renal | → | → |
Alogliptin | Once a day | Renal | → | → |